Skeletal muscle NAMPT is induced by exercise in humans

Am J Physiol Endocrinol Metab. 2010 Jan;298(1):E117-26. doi: 10.1152/ajpendo.00318.2009. Epub 2009 Nov 3.

Abstract

In mammals, nicotinamide phosphoribosyltransferase (NAMPT) is responsible for the first and rate-limiting step in the conversion of nicotinamide to nicotinamide adenine dinucleotide (NAD+). NAD+ is an obligate cosubstrate for mammalian sirtuin-1 (SIRT1), a deacetylase that activates peroxisome proliferator-activated receptor-gamma coactivator-1alpha (PGC-1alpha), which in turn can activate mitochondrial biogenesis. Given that mitochondrial biogenesis is activated by exercise, we hypothesized that exercise would increase NAMPT expression, as a potential mechanism leading to increased mitochondrial content in muscle. A cross-sectional analysis of human subjects showed that athletes had about a twofold higher skeletal muscle NAMPT protein expression compared with sedentary obese, nonobese, and type 2 diabetic subjects (P < 0.05). NAMPT protein correlated with mitochondrial content as estimated by complex III protein content (R(2) = 0.28, P < 0.01), MRS-measured maximal ATP synthesis (R(2) = 0.37, P = 0.002), and Vo(2max) (R(2) = 0.63, P < 0.0001). In an exercise intervention study, NAMPT protein increased by 127% in sedentary nonobese subjects after 3 wk of exercise training (P < 0.01). Treatment of primary human myotubes with forskolin, a cAMP signaling pathway activator, resulted in an approximately 2.5-fold increase in NAMPT protein expression, whereas treatment with ionomycin had no effect. Activation of AMPK via AICAR resulted in an approximately 3.4-fold increase in NAMPT mRNA (P < 0.05) as well as modest increases in NAMPT protein (P < 0.05) and mitochondrial content (P < 0.05). These results demonstrate that exercise increases skeletal muscle NAMPT expression and that NAMPT correlates with mitochondrial content. Further studies are necessary to elucidate the pathways regulating NAMPT as well as its downstream effects.

Trial registration: ClinicalTrials.gov NCT00401791 NCT00402012.

Publication types

  • Clinical Trial
  • Comparative Study
  • Research Support, N.I.H., Extramural
  • Research Support, Non-U.S. Gov't
  • Research Support, U.S. Gov't, Non-P.H.S.

MeSH terms

  • Adenosine Triphosphate / metabolism
  • Adult
  • Cells, Cultured
  • Colforsin / pharmacology
  • Cross-Sectional Studies
  • Cytokines / genetics*
  • Cytokines / metabolism*
  • Diabetes Mellitus, Type 2 / metabolism
  • Diabetes Mellitus, Type 2 / physiopathology
  • Diabetes Mellitus, Type 2 / therapy
  • Exercise / physiology*
  • Exercise Therapy
  • Heat-Shock Proteins / metabolism
  • Humans
  • Life Style
  • Middle Aged
  • Mitochondria / enzymology
  • Muscle, Skeletal / cytology
  • Muscle, Skeletal / enzymology*
  • Myoblasts / cytology
  • Myoblasts / drug effects
  • Myoblasts / enzymology
  • Nicotinamide Phosphoribosyltransferase / genetics*
  • Nicotinamide Phosphoribosyltransferase / metabolism*
  • Obesity / metabolism
  • Obesity / physiopathology
  • Obesity / therapy
  • Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha
  • Physical Endurance / physiology*
  • RNA, Messenger / metabolism
  • Signal Transduction / drug effects
  • Signal Transduction / physiology
  • Sports
  • Transcription Factors / metabolism
  • Young Adult

Substances

  • Cytokines
  • Heat-Shock Proteins
  • PPARGC1A protein, human
  • Peroxisome Proliferator-Activated Receptor Gamma Coactivator 1-alpha
  • RNA, Messenger
  • Transcription Factors
  • Colforsin
  • Adenosine Triphosphate
  • Nicotinamide Phosphoribosyltransferase
  • nicotinamide phosphoribosyltransferase, human

Associated data

  • ClinicalTrials.gov/NCT00401791
  • ClinicalTrials.gov/NCT00402012